268 studies found for:    Exclude Unknown | Expanded Access Studies
Show Display Options
Rank Status Study
21 No longer available Compassionate Use of the Becker Expander/Breast Implant
Condition: Breast Reconstruction
Interventions: Device: Becker 50 Expander/Breast implant;   Device: Becker 25 Expander/Breast implant
22 Available Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
Conditions: Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma
Interventions: Drug: Ramucirumab;   Drug: Paclitaxel
23 Approved for marketing A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
24 Available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
25 No longer available Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Conditions: Major Depressive Disorder;   Fibromyalgia;   Diabetic Peripheral Neuropathic Pain;   Generalized Anxiety Disorder
Intervention: Drug: Duloxetine Hydrochloride
26 Approved for marketing Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
Conditions: Cystic Fibrosis;   Pseudomonas Aeruginosa
Intervention: Drug: Aztreonam lysine
27 No longer available A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer
Condition: the Treatment Hand-foot Syndrome Patients With Gastrointestinal Tumors or Breast Cancer, Who Are Treated With Capecitabine
Interventions: Device: Mapisal;   Other: Urea hand-foot cream
28 Available Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
Condition: Cholestasis of Parenteral Nutrition
Intervention: Drug: Omegaven 10%
29 Available Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Conditions: Hematologic Malignancies;   Inborn Errors of Metabolism Disorders;   Immune Deficiencies
Intervention: Biological: CliniMACS CD34 Reagent System
30 Available An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: Pasireotide long acting release formulation
31 Approved for marketing Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection
Condition: Varicella
Intervention: Drug: VariZIG™
32 Approved for marketing Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Conditions: Thoracic Aortic Aneurysm;   Penetrating Ulcers
Intervention: Device: Relay Thoracic Stent-Graft
33 No longer available Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)
Condition: Renal Failure
Intervention: Biological: Biological/Vaccine: Enriched Hematopoetic Stem Cell Transplant
34 No longer available Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients
Condition: Lung Transplant
Intervention: Drug: Cyclosporine Inhalation Solution
35 No longer available Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery
Condition: Liver Failure
Intervention: Device: ELAD®
36 No longer available Treatment Protocol of Replagal for Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Biological: agalsidase alfa
37 Available Keratoconus and Ectasia Treatment Plan
Conditions: Keratoconus;   Ectasia
Interventions: Other: Riboflavin Solution;   Device: UV-X Illumination System
38 No longer available XL999 Administered Intravenously to a Subject With Advanced Malignancies
Condition: Advanced Malignancy
Intervention: Drug: XL999
39 Approved for marketing Prometra's Utilization in Mitigating Pain II
Conditions: Intractable Pain;   Back Pain;   Leg Pain;   Arm Pain;   Trunk Pain
Intervention: Device: Prometra Programmable Pump
40 Available Emergency/Compassionate Use PFO Occluder
Conditions: Patent;   Foramen;   Ovale;   PFO
Intervention: Device: Device closure with the AMPLATZER PFO Occluder

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years